A Phase 3 interventional study of Dalbavancin and Dalbavancin-matching Placebo in Abscess, Wound Infection and Surgical Site Infection, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 78 sites in 12 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-09-28.
Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Abscess with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Abscess · United States.
Among the 80 studies in Abscess with a site in United States, this one is the 9th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2014, is one of 13 in phase 3, and was the 54th registered.
152 studies on the registry are indexed under Abscess; 22 are open to participants now.
Browse Abscess studies →4 of the 80 studies in Abscess with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Loyola University · Sites in United States
Ages 7–70
University of Rochester · Sites in United States
Ages 18+
University of Rochester · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Abscess studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 13 · Phase 4 9
First in 2003; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 698 is above the median of 110 across 120 interventional studies indexed under Abscess.
Median enrollment 114 across the 75 interventional studies, 420 across the 5 observational. Of the 72 that completed or were terminated, 45 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Durata Therapeutics Inc., an affiliate of Allergan plc, one of the names counted as AbbVie. Under that name alone:
Durata Therapeutics Inc., an affiliate of Allergan plc is the lead sponsor of 6 studies on the registry; none are open to participants now.
AbbVie has 8 studies filed under Abscess — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 80 studies in Abscess with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl \<30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl \<30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
Drug: Dalbavancin · Drug: Dalbavancin-matching Placebo
Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl \<30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl \<30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
Drug: Dalbavancin
Dalbavancin IV infusion over 30 minutes.
Also known as: DALVANCE®
Dalbavancin-matching placebo IV infusion over 30 minutes.
Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug
Clinical responder was defined as a participant who was alive and had received no rescue therapy for acute bacterial skin and skin structure infection (ABSSSI) prior to the 48-72 hour infection site assessment (if an antibiotic has been given for another reason, the participant will not be considered a non-responder for this reason); and examination of the participant's ABSSSI lesion demonstrates a decrease of ≥ 20% in lesion area (calculated as the longest length multiplied by the longest perpendicular width) relative to the baseline measurement.
Time frame: Up to 48-72 hours after the initiation of study drug
Percentage of Participants by Clinical Status at End of Treatment (EOT) and Final Visit (FV)
Clinical Success is defined as follows: For evaluation at EOT visit, lesion area must be decreased by ≥80% from baseline and at FV lesion area must be decreased by ≥90% from baseline; Temperature is ≤37.6°C; Local signs of tenderness to palpation and swelling/induration are no worse than mild; For evaluation at EOT visit, local signs of fluctuance and localized heat/warmth must be improved from baseline and no worse than mild, and at FV local signs of fluctuance and localized heat/warmth must be absent; for participants with a wound infection the severity of purulent drainage is improved and no worse than mild relative to baseline. Clinical Failure is defined as the opposite to success or if the participant died during the study period up to visit or received study therapy for ABSSSI beyond the protocol treatment period. Clinical status is Indeterminate if any of the data needed to determine clinical success or clinical failure were missing.
Time frame: End of Treatment (Day 14-15 after the initiation of study drug) and Final Visit (28 ±2 days after the initiation of study drug)
Percentage of Participants by Clinical Status Based on Localized Fluctuance and Heat/Warmth at End of Treatment (EOT)
Clinical Success was defined as localized fluctuance and heat/warmth that if present at Baseline must be improved and no worse than mild. Clinical Failure was defined as the opposite to success. Clinical status was Indeterminate if any of the data needed to determine clinical success or clinical failure were missing.
Time frame: EOT (Day 14-15)
Percentage of Participants by Investigator Assessment of Clinical Outcome
A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given. An unsuccessful outcome was the opposite of successful. An Indeterminate outcome was defined as any of the data needed to determine a successful or unsuccessful outcome were missing.
Time frame: Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 +/- 2 days)
Percentage of Participants Achieving Clinical Outcome of Success Based on Key Target Pathogen at Baseline
A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given.
Time frame: Day 3-4 and EOT (Day 14-15)
Percentage of Participants With Complete Resolution of Local Signs of Infection
Resolution of Local Signs of Infection that include absence of purulence/drainage, erythema, heat/localized warmth, pain/tenderness to palpation, fluctuance, and swelling/induration.
Time frame: Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 +/- 2 days)
Change From Baseline in Participant's Assessment of Pain
Using the Brief Pain Inventory Scale, participants rated their pain "right now" on a scale where: 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.
Time frame: Baseline (Day 0) to Day 3-4, Day 8, EOT (Day 14-15) and Final Visit (Day 28 + /- 2 days)
Percentage of Participants by Resource Utilization Categories
Resource Utilization Categories included: Any additional visits (including urgent care), Any additional procedures, Any additional tests, Any home visits or nursing care and Any ER Visits. The percentage of participants in each category is reported.
Time frame: Final Visit (Day 28 +/- 2 days)
Percentage of Participants by Skin and Soft Tissue Infection-Convenience (SSTI-C) Questionnaire: Overall Satisfaction Response
The SSTI-C Questionnaire is an 11-item self-reported questionnaire that measures subjective experiences of the participant. One of the items assessed was overall satisfaction with treatment. Participants answered the question: "Overall, how satisfied were you with your antibiotic treatment?" using one of the following responses: Extremely satisfied, Moderately satisfied, Not at all satisfied, Slightly satisfied and Very satisfied. The percentage of participants in each category is reported.
Time frame: EOT (Day 14-15)
| Milestone | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Started | 349 | 349 |
| Completed | 323 | 322 |
| Not completed | 26 | 27 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 14 | 14 |
| Withdrew: Reason not specified | 4 | 7 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Subject withdrew consent | 5 | 3 |
Clinical responder was defined as a participant who was alive and had received no rescue therapy for acute bacterial skin and skin structure infection (ABSSSI) prior to the 48-72 hour infection site assessment (if an antibiotic has been given for another reason, the participant will not be considered a non-responder for this reason); and examination of the participant's ABSSSI lesion demonstrates a decrease of ≥ 20% in lesion area (calculated as the longest length multiplied by the longest perpendicular width) relative to the baseline measurement.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug | 81.4 | 84.2 |
Clinical Success is defined as follows: For evaluation at EOT visit, lesion area must be decreased by ≥80% from baseline and at FV lesion area must be decreased by ≥90% from baseline; Temperature is ≤37.6°C; Local signs of tenderness to palpation and swelling/induration are no worse than mild; For evaluation at EOT visit, local signs of fluctuance and localized heat/warmth must be improved from baseline and no worse than mild, and at FV local signs of fluctuance and localized heat/warmth must be absent; for participants with a wound infection the severity of purulent drainage is improved and no worse than mild relative to baseline. Clinical Failure is defined as the opposite to success or if the participant died during the study period up to visit or received study therapy for ABSSSI beyond the protocol treatment period. Clinical status is Indeterminate if any of the data needed to determine clinical success or clinical failure were missing.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| EOT; Clinical Success | 84.0 | 84.8 |
| EOT; Clinical Failure | 12.0 | 10.3 |
| EOT; Indeterminate | 4.0 | 4.9 |
| FV; Clinical Success | 84.5 | 85.1 |
| FV; Clinical Failure | 8.0 | 7.2 |
| FV; Indeterminate | 7.4 | 7.3 |
Clinical Success was defined as localized fluctuance and heat/warmth that if present at Baseline must be improved and no worse than mild. Clinical Failure was defined as the opposite to success. Clinical status was Indeterminate if any of the data needed to determine clinical success or clinical failure were missing.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Clinical Success | 84.8 | 85.4 |
| Clinical Failure | 7.7 | 6.9 |
| Indeterminate | 7.4 | 7.7 |
A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given. An unsuccessful outcome was the opposite of successful. An Indeterminate outcome was defined as any of the data needed to determine a successful or unsuccessful outcome were missing.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Successful Outcome (Day 3-4) | 93.4 | 93.0 |
| Unsuccessful Outcome (Day 3-4) | 0.3 | 0.9 |
| Indeterminate (Day 3-4) | 6.3 | 6.1 |
| Successful Outcome (Day 8) | 92.2 | 93.3 |
| Unsuccessful Outcome (Day 8) | 0.6 | 0.3 |
| Indeterminate (Day 8) | 7.2 | 6.4 |
| Successful Outcome (EOT) | 92.5 | 92.7 |
| Unsuccessful Outcome (EOT) | 2.9 | 1.5 |
| Indeterminate (EOT) | 4.6 | 5.8 |
| Successful Outcome (Final Visit) | 90.2 | 91.0 |
| Unsuccessful Outcome (Final Visit) | 2.6 | 1.7 |
| Indeterminate (Final Visit) | 7.2 | 7.3 |
A successful outcome was based on resolution or improvement of all signs and symptoms of the infection to such an extent that no further antibacterial treatment was given.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Staphylococcus aureus (Day 3-4) | 88.5 | 85.3 |
| Streptococcus agalactiae (Day 3-4) | 100.0 | 66.7 |
| Streptococcus anginosus group (Day 3-4) | 93.9 | 100.0 |
| Streptococcus dysgalactiae (Day 3-4) | 100.0 | 100.0 |
| Streptococcus pyogenes (Day 3-4) | 100.0 | 81.8 |
| Enterococcus faecalis (Day 3-4) | 100.0 | 80.0 |
| Staphylococcus aureus (EOT) | 87.8 | 91.7 |
| Streptococcus agalactiae (EOT) | 83.3 | 83.3 |
| Streptococcus anginosus group (EOT) | 81.8 | 89.5 |
| Streptococcus dysgalactiae (EOT) | 100.0 | 100.0 |
| Streptococcus pyogenes (EOT) | 92.9 | 81.8 |
| Enterococcus faecalis (EOT) | 100.0 | 100.0 |
Resolution of Local Signs of Infection that include absence of purulence/drainage, erythema, heat/localized warmth, pain/tenderness to palpation, fluctuance, and swelling/induration.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Day 3-4 | 1.9 | 1.5 |
| Day 8 | 22.3 | 21.1 |
| EOT Visit | 56.3 | 56.2 |
| Final Visit | 85.8 | 89.8 |
Using the Brief Pain Inventory Scale, participants rated their pain "right now" on a scale where: 0=no pain to 10=pain as bad as you can imagine. A negative change from Baseline indicated improvement.
| Scores on a scale | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Baseline | 7.7 ± 2.09 | 7.8 ± 2.12 |
| Change from Baseline to Day 3-4 | -3.9 ± 2.46 | -3.8 ± 2.43 |
| Change from Baseline to Day 8 | -5.9 ± 2.53 | -5.8 ± 2.68 |
| Change from Baseline to EOT Visit | -6.9 ± 2.37 | -6.9 ± 2.53 |
| Change from Baseline to Final Visit | -7.5 ± 2.19 | -7.4 ± 2.40 |
Resource Utilization Categories included: Any additional visits (including urgent care), Any additional procedures, Any additional tests, Any home visits or nursing care and Any ER Visits. The percentage of participants in each category is reported.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Any Additional Visits (including Urgent Care) | 1.2 | 0.6 |
| Any Additional Procedures | 1.5 | 1.6 |
| Any Additional Tests | 1.9 | 2.8 |
| Any Home Visits or Home Nursing Care | 1.5 | 1.2 |
| Any ER Visits | 0.3 | 0.9 |
The SSTI-C Questionnaire is an 11-item self-reported questionnaire that measures subjective experiences of the participant. One of the items assessed was overall satisfaction with treatment. Participants answered the question: "Overall, how satisfied were you with your antibiotic treatment?" using one of the following responses: Extremely satisfied, Moderately satisfied, Not at all satisfied, Slightly satisfied and Very satisfied. The percentage of participants in each category is reported.
| percentage of participants | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Extremely Satisfied | 53.6 | 56.9 |
| Moderately Satisfied | 9.5 | 7.2 |
| Not at all Satisfied | 0.9 | 0.9 |
| Slightly Satisfied | 0.3 | 0.9 |
| Very Satisfied | 35.8 | 33.7 |
Collected over Up to 28 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-Dose Dalbavancin | 1/349 (0.3%) | 7/349 (2%) | 0/349 (0%) |
| Two-Dose Dalbavancin | 1/346 (0.3%) | 5/346 (1.4%) | 0/346 (0%) |
| Event | Single-Dose Dalbavancin | Two-Dose Dalbavancin |
|---|---|---|
| Skin bacterial infectionInfections and infestations | 2/349 | 0/346 |
| Clostridium difficile colitisInfections and infestations | 0/349 | 1/346 |
| Necrotising fasciitisInfections and infestations | 0/349 | 1/346 |
| Renal failure acuteRenal and urinary disorders | 0/349 | 1/346 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/349 | 1/346 |
| UrticariaSkin and subcutaneous tissue disorders | 0/349 | 1/346 |
| Vitreous haemorrhageEye disorders | 1/349 | 0/346 |
| PneumoniaInfections and infestations | 1/349 | 0/346 |
| SepsisInfections and infestations | 1/349 | 0/346 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/349 | 0/346 |
Intent-to-treat (ITT) Population included all randomized participants.
| Age, Continuous(years) | Single-Dose Dalbavancin | Two-Dose Dalbavancin | Total |
|---|---|---|---|
| Mean | 48.0 ± 14.83 | 48.3 ± 14.74 | 48.2 ± 14.78 |
| Sex: Female, Male(Participants) | Single-Dose Dalbavancin | Two-Dose Dalbavancin | Total |
|---|---|---|---|
| Female | 145 | 146 | 291 |
| Male | 204 | 203 | 407 |
Ran from Apr 2014 to primary completion in Mar 2015, 10 months.
Results were first posted in Aug 2018, 3 years 5 months after primary completion. A results delay was requested in May 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalbavancin
Durata Therapeutics Inc., an affiliate of Allergan plc →